Genes are small segments of DNA that instruct your cells to make certain proteins when specific conditions are met.
Mutated genes, on the other hand, may cause your cells to make too much or too little of the necessary protein. Even small changes can have a domino effect across your body just as tiny changes in computer code can affect an entire program.
Viral vectors
Scientists dont have tweezers small enough to edit your DNA by hand. Instead, they recruit a surprising ally to work on their behalf: viruses.
Typically, a virus would enter your cells and alter your DNA to create more copies of itself. But scientists can switch out this programming with their own, hijacking the virus to heal instead of harm. These vectors, as theyre called, dont have the parts they need to cause disease, so they cant make you sick the way a regular virus could.
There are two types of gene therapy:
Gene therapy is different from genetic engineering, which means changing otherwise healthy DNA for the purpose of enhancing specific traits. Hypothetically, genetic engineering could potentially reduce a childs risk of certain diseases or change the color of their eyes. But the practice remains highly controversial since it hovers very close to eugenics.
Gene therapy may be used to treat a variety of genetic conditions, including:
Inherited vision loss
When the RPE65 gene in your retinas doesnt work, your eyeballs cant convert light to electrical signals.
The gene therapy Luxturna, approved by the Food and Drug Administration (FDA) in 2017, can deliver a functional replacement of the RPE64 gene to your retinal cells.
Blood disorders
The FDA-approved Hemgenix can treat the bleeding disorder hemophilia B. The viral vector instructs your liver cells to create more of the factor IX protein, which helps your blood clot.
Meanwhile, the gene therapy Zynteglo, approved by the FDA in 2022, treats beta-thalassemia by giving your bone marrow stem cells correct instructions for creating hemoglobin.
This blood disorder can lower the oxygen in your body because it decreases your bodys hemoglobin production.
Spinal muscular atrophy (SMA)
In infantile-onset SMA, an infants body cant make enough of the survival of motor neuron (SMN) proteins necessary to build and repair motor neurons. Without these neurons, infants gradually lose their ability to move and breathe.
The gene therapy Zolgensma, approved by the FDA in 2019, replaces faulty SMN1 genes in an infants motor cells with genes that can create enough SMN proteins.
Cerebral adrenoleukodystrophy (CALD)
Your ABCD1 gene produces an enzyme that breaks down fatty acids in your brain. If you have cerebral adrenoleukodystrophy, this gene is either broken or missing.
Skysona, FDA approved as of 2022, delivers a functional ABCD1 gene so that fatty acids dont build up and cause brain damage.
Cancers
Most cancer gene therapies work indirectly by inserting new genes into a powerful antibody called a T cell. Your changed T cells can then latch on to cancerous cells and eliminate them, similar to how they attack viruses.
Some people considering gene therapy may feel uneasy about putting viruses in their body.
Keep in mind, though, that gene therapies undergo extensive testing before approval. The viruses in gene therapies are also fixed so they cant replicate similar to many vaccines.
That said, gene therapies may pose other risks:
Despite these issues, experts generally believe gene therapy offers more benefits than risks.
Most of the conditions treated with gene therapy are life threatening. The dangers of leaving them untreated often outweigh the risks of potential side effects.
Gene therapy does come with a few drawbacks that keep it from becoming a widespread treatment.
Limited targets
Gene therapy can only target certain mutations. This means it may not work for everyone with a specific condition.
For example, two people may have inherited vision loss. Currently, gene therapy can only treat vision loss caused by the RPE64 mutation.
Time to approval
Because gene therapy research is so new, experts do extensive safety testing before introducing their treatments to the public. It can take years to get FDA approval for each new therapy.
Expense
As you might imagine, gene therapies are expensive to manufacture and administer. This not only affects funding for clinical trials but also the price of the drug.
For example, the gene therapy Zolgensma is the most expensive drug in the United States at $2.1 million per dose. Even with insurance, that kind of price tag remains out of reach for the average American.
Scientists are trying to find ways to make the development process safer, cheaper, and more efficient so more people can access gene therapy.
Gene therapy works to treat several different genetic diseases by editing the mutations that cause them. As researchers further refine and expand this technology, they may find even more conditions that could be treated with it.
Experts are also continuing to explore options to make gene therapy more affordable so people who need these treatments have an easier time getting them.
Emily Swaim is a freelance health writer and editor who specializes in psychology. She has a BA in English from Kenyon College and an MFA in writing from California College of the Arts. In 2021, she received her Board of Editors in Life Sciences (BELS) certification. You can find more of her work on GoodTherapy, Verywell, Investopedia, Vox, and Insider. Find her on Twitter and LinkedIn.
Here is the original post:
How Does Gene Therapy Work? Types, Uses, Safety - Healthline
- Gene therapy: What is it and how does it work? | Live Science - September 21st, 2024
- In race to make gene therapy for age-related blindness, 4D Molecular announces positive results - STAT - September 21st, 2024
- Penn gene therapy pioneer Jim Wilson explains why he's leaving - The Business Journals - September 21st, 2024
- Whats the Meaning of Cure in Gene Therapy? - Managed Healthcare Executive - September 21st, 2024
- Ori doubles down on Charles River collaboration with promising new data on its automated cell therapy platform - FiercePharma - September 21st, 2024
- Doctors cured her sickle-cell disease. So why is she still in pain? - Nature.com - September 21st, 2024
- Gene Therapy Company Increases Focus on Mesothelioma Program - Mesothelioma.net Blog - September 21st, 2024
- Sickle cell gene therapies roll out slowly : Shots - Health News - NPR - September 21st, 2024
- Patients At Last Begin Receiving Vertex-CRISPR and Bluebird Sickle Cell Gene Therapies - BioSpace - September 21st, 2024
- Beacon Therapeutics Presents 36-Month Interim Results from Phase I/2 HORIZON Trial of AGTC-501 in Patients with XLRP - PR Newswire - September 21st, 2024
- Beacons Gene Therapy Shows Continued Promise in Trial - TipRanks - September 21st, 2024
- How stem cell and gene therapies are revolutionising healthcare - Express Healthcare - September 21st, 2024
- Nanoscope Therapeutics to be Featured at Annual EUretina Congress in Barcelona - PR Newswire - September 21st, 2024
- 6-year-old Tennessee boy denied potentially life-saving gene therapy by insurance company - WCYB - September 21st, 2024
- Seeking a sickle cell cure: 12-year-old in DC is 1st patient in US to get new gene therapy - NBC Washington - May 24th, 2024
- Game-changer: The Hindu Editorial on approval for gene therapy to treat sickle cell disease and beta thalassemia - The Hindu - December 13th, 2023
- Early trials show promise for innovative gene therapy in lung cancer treatment - WJAR - October 16th, 2023
- Cell and Gene Therapy Manufacturing Quality Control Market Growing Trends and Technology Forecast to 2029 |... - SeeDance News - October 16th, 2023
- How Gene Therapy Can Cure or Treat Diseases | FDA - March 21st, 2023
- Genetic Therapies - What Are Genetic Therapies? | NHLBI, NIH - March 21st, 2023
- FDA approves novel gene therapy to treat patients with a rare form of ... - December 28th, 2022
- Gene Therapy - Discover How It Works Its Types And Applications - BYJUS - December 28th, 2022
- IVERIC bio Subsidiary Sells Assets of Gene Therapy Product Candidates for Treatment of Retinal Diseases - Marketscreener.com - December 28th, 2022
- Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th... - October 31st, 2022
- Decibel Therapeutics Receives FDA Clearance of IND Application for DB-OTO, a Gene Therapy Product Candidate Designed to Provide Hearing to Individuals... - October 23rd, 2022
- NIH researchers develop gene therapy for rare ciliopathy - National Institutes of Health (.gov) - September 12th, 2022
- Engensis Gene Therapy for ALS Found Safe in Small Phase 2a Trial |... - ALS News Today - September 12th, 2022
- Global Cancer Gene Therapy Market Report 2022: Benefits of Gene Therapy Over Conventional Therapies Driving Adoption - ResearchAndMarkets.com -... - September 12th, 2022
- As Philly becomes a hub for life sciences, a new program will train workers for jobs in the field - The Philadelphia Inquirer - September 12th, 2022
- Myrtelle's rAAV-Olig001-ASPA Gene Therapy Candidate for Canavan Disease Receives Advanced Therapy Medicinal Product Classification from the European... - September 12th, 2022
- Charles River and Cure AP-4 Announce Gene Therapy Manufacturing Collaboration - Business Wire - September 12th, 2022
- Urovant Sciences Receives Best in Category Award for Abstract Highlighting Investigational Novel Gene Therapy, URO-902, Presented at 2022... - September 12th, 2022
- The gene therapy that could transform the lives of millions - ABC News - September 12th, 2022
- Carroucell Raises 1.5 Million to Introduce Breakthrough Microcarriers and Customizable Processes to Cell and Gene Therapy Market - Business Wire - September 12th, 2022
- Solving medical mysteries with genetics: The Penn Neurogenetics Therapy Center | Penn Today - Penn Today - September 12th, 2022
- George Clinical Expands China Team with New Project Director and Cell Gene Therapy Head Helen Xu - AsiaOne - September 12th, 2022
- IIT-B-Tata hosp cancer therapy trials show promising results - Hindustan Times - September 12th, 2022
- 7th International Congress of Myology Nice - EurekAlert - September 12th, 2022
- Discovery advances the potential of gene therapy to restore hearing loss - Salk Institute - August 11th, 2022
- Health and Tech: The promise of gene therapy to cure cancers - Telangana Today - August 11th, 2022
- Global Gene Therapy Market 2022-2027: High Incidence of Cancer & Other Targeted Diseases to Drive Growth - ResearchAndMarkets.com - Business Wire - August 11th, 2022
- Global Gene Therapy Market Report 2022: Type of Therapy, Gene Delivery Method, Type of Vector Used, Target Therapeutic Areas, Route of Administration... - August 11th, 2022
- Potentiation of combined p19Arf and interferon-beta cancer gene therapy through its association with doxorubicin chemotherapy | Scientific Reports -... - August 11th, 2022
- bluebird bio reveals plans to launch two gene therapies - PMLiVE - August 11th, 2022
- Taysha Gene Therapies to Release Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11 - GlobeNewswire - August 11th, 2022
- The Alliance for Regenerative Medicine Announces the Appointment of Timothy D. Hunt as Chief Executive Officer - Yahoo Finance - August 11th, 2022
- Adverum Biotechnologies to Participate in the 2nd Annual H.C. Wainwright Ophthalmology Virtual Conference - Yahoo Finance - August 11th, 2022
- Stem Cell Therapy Global Market Report 2022: Rapid Growth in Emerging Markets & An Increase in Investments in Cell and Gene Therapies Driving... - August 11th, 2022
- OHSU advancing first-of-its-kind strategy to overcome infertility - OHSU News - August 11th, 2022
- Intracranial Therapeutic Delivery Market revenue will climb to US$ 4.2 Bn by the end of 2032 Persistence Market Research - GlobeNewswire - August 11th, 2022
- Is This Company In A Special Position Even As The COVID-19 Pandemic Affects Cell-Based Therapy Industry? - Benzinga - August 11th, 2022
- At ISCT This Week, Cell & Gene Therapy Grows Up - BioSpace - May 8th, 2022
- Tenaya Therapeutics to Present Preclinical Data on Gene Therapy Programs and Platform Capabilities at the American Society of Gene and Cell Therapy... - May 8th, 2022
- BioMarin to Present Findings from Ongoing Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the World Federation of Hemophilia... - May 8th, 2022
- Top 12 Emerging Gene and Cell Therapy Technologies Likely to Impact Patient Care Announced in Annual Disruptive Dozen from Mass General Brigham - Mass... - May 8th, 2022
- Mustang Bio Announces Data on Treatment with Lentiviral Viral Vector Gene Therapy for X-Linked Severe Combined Immunodeficiency Selected for Oral... - May 8th, 2022
- OPC UA for Sample Process Automation Improving Data Harmonization for Biobanks and Cell and Gene Therapies - Technology Networks - May 8th, 2022
- Alcyone Announces Two Oral Presentations on its Gene Therapy Platforms at the 25th American Society of Gene and Cell Therapy (ASGCT) Annual Meeting -... - May 8th, 2022
- Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting - GlobeNewswire - May 8th, 2022
- New treatment for infants with weakened immune systems - Sciworthy - May 8th, 2022
- Selecta Biosciences Announces Six Presentations at the Upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) - Yahoo... - May 8th, 2022
- CODA Biotherapeutics Announces Preclinical Data From Epilepsy Program to be Presented at American Society of Gene & Cell Therapy 25th Annual... - May 8th, 2022
- Gene Therapy Cell Culture Media Market Scope and overview, To Develop with Increased Global Emphasis on Industrialization 2029 Fujifilm Holdings... - May 8th, 2022
- Research Roundup: COVID-19 Cognitive Impairment Equal to 20 Years of Aging - BioSpace - May 8th, 2022
- International Thalassaemia Day 2022: The genetic perspective of Thalassemia - Free Press Journal - May 8th, 2022
- Opus Genetics Announces Promising New Data Highlighting Potential of AAV-based Gene Therapies for the Tre - Benzinga - May 8th, 2022
- Virica Biotech Announces Collaboration with the Government of Canada - Business Wire - May 8th, 2022
- Tenaya Thearpeutics Reports Will Present Preclinical Data On Gene Therapy Programs, Platform Capabilities - Benzinga - May 8th, 2022
- Precision BioSciences to Present Preclinical In Vivo Gene Editing Research at Upcoming American Society of Gene & Cell Therapy 25th Annual Meeting... - May 8th, 2022
- Catalent introduces cryogenic capabilities to support growing demand for cell and gene therapy - gasworld - April 17th, 2021
- Bioprocessing and Bioproduction Trends in Cell and Gene Therapies - Technology Networks - April 17th, 2021
- Alliance for Cancer Gene Therapy Summit 2021 Features World Renowned Cancer Researchers Advancing Solid Tumor Breakthroughs - WFMZ Allentown - April 17th, 2021
- Gene therapy startup StrideBio signs collaboration deal with Duke University - WRAL Tech Wire - April 17th, 2021
- Cell and gene therapy services market forecast to see significant growth over the next decade - BioPharma-Reporter.com - April 17th, 2021
- TeamedOn and AGTC Announce a Licensing Agreement Advancing X-Linked Retinoschisis Gene Therapy Program - BioSpace - April 17th, 2021
- Jaguar Gene Therapy gains $139 million from investors - Daily Herald - April 17th, 2021
- Medically Necessary: Growth of biologics and gene therapies means more cold chain - FreightWaves - April 17th, 2021
- Taysha Gene Therapies Announces New Data on Multiple Preclinical Programs and Upcoming R&D Day - BioSpace - April 17th, 2021
- From gene therapies to medical treatments, cutting-edge research finds a home in NC - WRAL.com - April 17th, 2021
- University of Cambridge research suggests gene therapies offer hope in treating glaucoma and dementia - Cambridge Independent - April 17th, 2021
Tags: